サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：心臓補助装置の世界市場-2023年～2030年
市場調査レポート
商品コード
1373386

心臓補助装置の世界市場-2023年～2030年

Global Cardiac Assist Devices Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 187 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
心臓補助装置の世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

心臓補助循環装置（CAD）は、重症の心臓病患者の循環機能をサポートする血液ポンプです。これは、心臓がより多くの血液を送り出すのを助けるように設計された機械的ポンプ装置です。心臓から送り出された血液を全身に送り出すことで心臓の負担を軽減します。

ペースメーカーは胸部に装着する小型の医療機器で、電気パルスを使用して心臓が正常な範囲で拍動するよう促すことで、異常な心臓のリズムをコントロールするのに役立ちます。心臓補助装置は現在、心臓移植への橋渡しとして重症心不全の治療に一般的に使用されています。

市場力学：促進要因・抑制要因

心不全患者数の増加

心不全患者の増加により、心臓補助装置の使用と応用が増加します。補助人工心臓は、体の他の部位から心臓へ血液を送り込むのに役立ちます。

例えば、2022年に発表された報告書によると、心不全の有病率は世界で2,600万人と推定され、世界のヘルスケアコストの増加に寄与しています。心不全は、高い罹患率と死亡率を伴う疾患として、世界的に依然として高い頻度で蔓延しています。

さらに、AHAジャーナルが発表した報告書によると、心不全の有病率は600万人と推定され、これは米国総人口の約1.8％にあたります。また、調査によると、2030年までに心不全有病率は46％増加し、米国では800万人以上に達すると予測されています。したがって、心不全患者数の増加は市場の成長を高めると予想されます。

抑制要因

機器と手技のコスト高

装置や処置にかかる費用の増加は、市場成長の妨げとなる可能性があります。初回入院を含む123日間の治療にかかる総費用は、LVADが197,957米ドル、心臓移植が151,646米ドルです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 心不全患者数の増加
    • 抑制要因
      • 機器や処置に伴う高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 製品別

  • 補助人工心臓
  • 完全人工心臓
  • 大動脈内バルーンポンプ
  • その他

第8章 用途別

  • ブリッジ・ツー・トランスプラント（BTT）療法
  • 目的地治療
  • その他

第9章 エンドユーザー別

  • 病院
  • クリニック
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Medtronic Plc
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Abiomed Inc.
  • SynCardia Systems
  • Calon Cardio-Technology Ltd.
  • Teleflex Incorporated
  • Abbott Laboratories
  • BiVACOR Inc.
  • Berlin Heart GmbH
  • EVAHEART, INC.
  • Jarvik Heart, Inc.

第13章 付録

目次
Product Code: MD1856

Overview

Cardiac assist devices (CAD) are blood pumps that support the circulatory functions of severely ill cardiac patients. These are mechanical pumping devices designed to help the heart pump more blood. They work by taking blood from the heart and pumping it to the rest of the body, thus taking the burden off the heart.

These are small medical devices placed in the chest, a pacemaker helps control abnormal heart rhythms by using electrical pulses to prompt the heart to beat at a normal range. Cardiac assist devices are now commonly used in the treatment of severe heart failure as bridges to cardiac transplants.

Market Dynamics: Drivers & Restraints

Increase in the number of heart failure cases

An increase in the number of heart failure cases will increase the usage and application of cardiac assist devices. They help in pumping blood to the heart from other parts of the body.

For instance, according to the report published in 2022, it is estimated that heart failure has an estimated prevalence of 26 million people worldwide and contributes to increased healthcare costs worldwide. Heart failure remains a highly prevalent disorder worldwide with a high morbidity and mortality rate.

Additionally, according to the report published by AHA Journal, it is estimated that the prevalence of heart failure is 6 million, approximately 1.8% of the total US population. It also said that researchers have predicted a 46% increase in heart failure prevalence by 2030, reaching more than 8 million people in the US. Thus, the increase in the number of heart failures is expected to raise the market growth.

Restraint

High costs of devices and the procedures

Increasing costs for the devices and procedures can hamper the market growth, as only few individuals can afford the treatment procedure cost. The overall cost for the 123 days of care including initial hospitalization was $197 957 for LVADs and $151 646 for heart transplants.

Segment Analysis

The global cardiac assist devices market is segmented based on product, application, end-user, and region.

Ventricular assist device segment accounted for 48.3% of the market share

Ventricular assist devices segment is expected to hold a dominant share in the global cardiac assist devices market. A ventricular assist device (VAD) is a device that helps pump blood from the lower chambers of the heart to the rest of the body. The advantages of the devices over other types are holding the segment in the dominant position.

Left Ventricular Assist Devices (LVADs) are mechanical devices that are implanted in patients with advanced heart failure, help the heart pump blood more effectively, and could benefit patients with advanced heart failure as they await donors. They improve the function of the kidneys, liver, brain, and other organs by increasing blood flow to the body.

Additionally, the increase in the number of heart diseases, and increase in the geriatric population, and the increase in the number of launches of the devices are expected to drive the segment's growth. Thus, the above factors are expected to hold a significant position in the market share.

Geographical Analysis

North America is expected to hold a significant position in the global cardiac assist devices market share

North America holds a dominant share in the cardiac assist devices market share owing to the technological advancements in the field of cardiac assist devices and the rise in the prevalence of heart diseases which is expected to continue throughout the forecast period.

For instance, on July 11, 2023, SynCardia Systems, LLC., received the U.S. Food and Drug Administration (FDA) approval for the update of the SynCardia TAH-t label with real-world data further confirming the safety and performance of the Companion 2 Driver.

Additionally, on August 29, 2022, has released new late-breaking data that show its HeartMate 3 heart pump extends the survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later-stage disease for which it has received the US approval in 2020. Thus, the above factors are expected to drive the market growth in this region.

COVID-19 Impact Analysis:

The COVID-19 has impacted the cardiac assist devices market negatively. The reduction in the number of cardiovascular surgeries and the closure of hospitals during the period of lockdown has impacted the market growth. People refused to visit hospitals for treatment procedures because of the spread of the virus.

Competitive Landscape

The leading companies with a significant market share include: Medtronic Plc, Abiomed Inc., SynCardia Systems, Calon Cardio-Technology Ltd., Teleflex Incorporated, Abbott Laboratories, BiVACOR Inc., Berlin Heart GmbH, EVAHEART, INC., and Jarvik Heart, Inc.

Key Developments

  • On January 24, 2023, Terumo, Japan's largest maker of medical supplies, established a wholly-owned subsidiary in the US. It has launched the US LVAD (left ventricular heart assist device) business.
  • On June 26, 2021, CARMAT introduced the first implant of its Aeson bioprosthetic artificial heart in Germany.

Why Purchase the Report?

  • To visualize the global cardiac assist devices market segmentation based on product, application, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cardiac assist devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global cardiac assist devices market report would provide approximately 59 tables, 61 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in the number of heart failure cases
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. High costs associated with the devices and procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Ventricular Assist Device *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Total Artificial Heart
  • 7.4. Intra-Aortic Balloon Pump
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Bridge-to-transplant (BTT) Therapy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Destination Therapy
  • 8.4. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Clinics
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic Plc *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Abiomed Inc.
  • 12.3. SynCardia Systems
  • 12.4. Calon Cardio-Technology Ltd.
  • 12.5. Teleflex Incorporated
  • 12.6. Abbott Laboratories
  • 12.7. BiVACOR Inc.
  • 12.8. Berlin Heart GmbH
  • 12.9. EVAHEART, INC.
  • 12.10. Jarvik Heart, Inc.

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us